Ben George, M.B.B.S., M.D.

  1. Oncologist
  1. Bo AY, Cheng YC, George B, Kilari D, Thompson JR, Jorns JM. Online Portal Use of Pathology Reports in Patients With Solid Tumors. Arch Pathol Lab Med. 2025 Aug 1; 149 (8):734-740
    View PubMed
  2. DeVoe E, Reddi HV, Taylor BW, Stachowiak S, Geurts JL, George B, Shaker R, Urrutia R, Zimmermann MT. An Analytical Approach that Combines Knowledge from Germline and Somatic Mutations Enhances Tumor Genomic Reanalyses in Precision Oncology. J Comput Biol. 2025 Jan; 32 (1):89-103 Epub 2024 Dec 11
    View PubMed
  3. Beltran Ponce SE, Small CJ, Ahmad T, Patel K, Tsai S, Kamgar M, George B, Kharofa JR, Saeed H, Dua KS, Clarke CN, Aldakkak M, Evans DB, Christians K, Paulson ES, Erickson B, Hall WA. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Pract Radiat Oncol. 2025 Jan-Feb; 15 (1):e47-e56 Epub 2024 Sept 07
    View PubMed
  4. Wahida A, George B, Kurzrock R. At the right time: Moving precision therapy to newly diagnosed cancer. Med. 2024 Dec 13; 5 (12):1463-1465
    View PubMed
  5. Thapa B, Shreenivas A, Bylow K, Chen HZ, George B, Kurzrock R. Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases. J Immunother Precis Oncol. 2024 Nov; 7 (4):308-313 Epub 2024 Nov 01
    View PubMed
  6. Shitara K, Falcone A, Fakih MG, George B, Sundar R, Ranjan S, Van Cutsem E. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. Oncologist. 2024 May 3; 29 (5):e601-e615
    View PubMed
  7. George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2024 May; 166 (5):859-871.e3 Epub 2024 Jan 25
    View PubMed
  8. de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans DB, Christians KK, Clarke CN, George B, Shreenivas A, Kamgar M, Chakrabarti S, Dua KS, Khan AH, Madhavan S, Erickson BA, Hall WA. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Cancer Med. 2024 Jan; 13 (1):e6582 Epub 2023 Dec 22
    View PubMed
  9. Mehdi M, Szabo A, Shreenivas A, Thomas JP, Tsai S, Christians KK, Evans DB, Clarke CN, Hall WA, Erickson B, Ahmed G, Thapa B, McFall T, George B, Kurzrock R, Kamgar M. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Ther Adv Med Oncol. 2024; 16:17588359241253113 Epub 2024 May 19
    View PubMed
  10. Thalji SZ, Fernando D, Dua KS, Madhavan S, Chisholm P, Smith ZL, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Evans DB, Tsai S. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Ann Surg. 2023 Dec 1; 278 (6):e1224-e1231 Epub 2023 Apr 20
    View PubMed
  11. Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ Precis Oncol. 2023 Sep 29; 7 (1):101 Epub 2023 Sept 29
    View PubMed
  12. Thalji SZ, Aldakkak M, Christians KK, Clarke CN, George B, Kamgar M, Erickson BA, Hall WA, Chisholm P, Kulkarni N, Doucette S, Evans DB, Tsai S. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. J Surg Oncol. 2023 Jul; 128 (1):41-50 Epub 2023 Apr 11
    View PubMed
  13. Moroney J, Trivella J, George B, White SB. A Paradigm Shift in Primary Liver Cancer Therapy Utilizing Genomics, Molecular Biomarkers, and Artificial Intelligence. Cancers (Basel). 2023 May 17; 15 (10)
    View PubMed
  14. Thalji SZ, Kamgar M, George B, Aldakkak M, Christians KK, Clarke CN, Erickson BA, Hall WA, Tolat PP, Smith ZL, Evans DB, Tsai S. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Ann Surg Oncol. 2023 May; 30 (5):3013-3021 Epub 2023 Feb 14
    View PubMed
  15. Matoska T, Banerjee A, Shreenivas A, Jurkowski L, Shukla ME, Gore EM, Linsky P, Gasparri M, George B, Johnstone C, Johnstone D, Puckett LL. Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer. Cancers (Basel). 2023 Apr 28; 15 (9)
    View PubMed
  16. Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Comprehensive genomic profiling: Does timing matter? Front Oncol. 2023; 13:1025367 Epub 2023 Feb 14
    View PubMed
  17. Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SL. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 Jan 1; 115 (1):202-213 Epub 2022 Sept 13
    View PubMed
  18. Van Cutsem E, Hochster H, Shitara K, Mayer R, Ohtsu A, Falcone A, Yoshino T, Doi T, Ilson DH, Arkenau HT, George B, Benhadji KA, Makris L, Tabernero J. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. ESMO Open. 2022 Dec; 7 (6):100633 Epub 2022 Nov 28
    View PubMed
  19. Tong L, George B, Crotty BH, Somai M, Taylor BW, Osinski K, Luo J. Telemedicine and health disparities: Association between patient characteristics and telemedicine, in-person, telephone and message-based care during the COVID-19 pandemic. IPEM Transl. 2022 Nov-Dec; 3:100010 Epub 2022 Oct 30
    View PubMed
  20. Ponce SEB, Erickson BA, Hall WA, Bedi M, Martens MJ, Siker M, Thomas J, George B, Ludwig K, Peterson C, Ridolfi T, Longo JM. Long term clinical outcomes and associated predictors of progression free survival in anal canal cancer. J Gastrointest Oncol. 2022 Feb; 13 (1):185-196
    View PubMed
  21. Das A, Sudhaman S, Morgenstern D, Coblentz A, Chung J, Stone SC, Alsafwani N, Liu ZA, Karsaneh OAA, Soleimani S, Ladany H, Chen D, Zatzman M, Cabric V, Nobre L, Bianchi V, Edwards M, Sambira Nahum LC, Ercan AB, Nabbi A, Constantini S, Dvir R, Yalon-Oren M, Campino GA, Caspi S, Larouche V, Reddy A, Osborn M, Mason G, Lindhorst S, Bronsema A, Magimairajan V, Opocher E, De Mola RL, Sabel M, Frojd C, Sumerauer D, Samuel D, Cole K, Chiaravalli S, Massimino M, Tomboc P, Ziegler DS, George B, Van Damme A, Hijiya N, Gass D, McGee RB, Mordechai O, Bowers DC, Laetsch TW, Lossos A, Blumenthal DT, Sarosiek T, Yen LY, Knipstein J, Bendel A, Hoffman LM, Luna-Fineman S, Zimmermann S, Scheers I, Nichols KE, Zapotocky M, Hansford JR, Maris JM, Dirks P, Taylor MD, Kulkarni AV, Shroff M, Tsang DS, Villani A, Xu W, Aronson M, Durno C, Shlien A, Malkin D, Getz G, Maruvka YE, Ohashi PS, Hawkins C, Pugh TJ, Bouffet E, Tabori U. Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022 Jan; 28 (1):125-135 Epub 2022 Jan 06
    View PubMed
  22. Kamgar M, Chakrabarti S, Shreenivas A, George B. Evolution of Systemic Therapy in Metastatic Pancreatic Ductal Adenocarcinoma. Surg Oncol Clin N Am. 2021 Oct; 30 (4):673-691 Epub 2021 July 22
    View PubMed
  23. George B. Precision Medicine and Pancreatic Cancer. Surg Oncol Clin N Am. 2021 Oct; 30 (4):693-708
    View PubMed
  24. Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 Sep; 22(9):1290-1300. Epub 2021 Jul 30.
    View PubMed
  25. Hall WA, Kamgar M, Erickson BA, Ponce SB, Tsai S, Nevalainen MT, Christians KK, George B, Dua KS, Khan AH, Evans DB, Azmi AS. Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Cancer Metastasis Rev. 2021 Sep; 40 (3):879-889 Epub 2021 Oct 06
    View PubMed
  26. Luo J, Tong L, Crotty BH, Somai M, Taylor B, Osinski K, George B. Telemedicine Adoption during the COVID-19 Pandemic: Gaps and Inequalities. Appl Clin Inform. 2021 Aug; 12 (4):836-844 Epub 2021 Sept 08
    View PubMed
  27. Mora J, Krepline AN, Aldakkak M, Christians KK, George B, Hall WA, Erickson BA, Kulkarni N, Evans DB, Tsai S. Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. Am J Surg. 2021 Jul; 222 (1):10-17 Epub 2020 Dec 03
    View PubMed
  28. Stachowiak S, Jacquart A, Zimmermann MT, George B, Dong H, Geurts JL. Germline evaluation of patients undergoing tumor genomic profiling: An academic cancer center's experience with implementing a germline review protocol. J Genet Couns. 2021 Jun; 30 (3):900-910 Epub 2021 Mar 22
    View PubMed
  29. Chung J, Maruvka YE, Sudhaman S, Kelly J, Haradhvala NJ, Bianchi V, Edwards M, Forster VJ, Nunes NM, Galati MA, Komosa M, Deshmukh S, Cabric V, Davidson S, Zatzman M, Light N, Hayes R, Brunga L, Anderson ND, Ho B, Hodel KP, Siddaway R, Morrissy AS, Bowers DC, Larouche V, Bronsema A, Osborn M, Cole KA, Opocher E, Mason G, Thomas GA, George B, Ziegler DS, Lindhorst S, Vanan M, Yalon-Oren M, Reddy AT, Massimino M, Tomboc P, Van Damme A, Lossos A, Durno C, Aronson M, Morgenstern DA, Bouffet E, Huang A, Taylor MD, Villani A, Malkin D, Hawkins CE, Pursell ZF, Shlien A, Kunkel TA, Getz G, Tabori U. DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. Cancer Discov. 2021 May; 11 (5):1176-1191 Epub 2020 Dec 18
    View PubMed
  30. Kim RY, Christians KK, Aldakkak M, Clarke CN, George B, Kamgar M, Khan AH, Kulkarni N, Hall WA, Erickson BA, Evans DB, Tsai S. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol. 2021 Apr; 28 (4):2246-2256 Epub 2020 Sept 30
    View PubMed
  31. Abid MB, Chhabra S, Buchan B, Graham MB, Abedin S, Thapa B, D'Souza A, George B, Hamadani M. Bronchoalveolar lavage-based COVID-19 testing in patients with cancer. Hematol Oncol Stem Cell Ther. 2021 Mar; 14(1):65-70. Epub 2020 Oct 08.
    View PubMed
  32. Krepline AN, Geurts JL, George B, Kamgar M, Madhavan S, Erickson BA, Hall WA, Griffin MO, Evans DB, Tsai S, Kim RY. Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. Surgery. 2021 Mar; 169 (3):629-635 Epub 2020 Aug 18
    View PubMed
  33. George B, Kent M, Surinach A, Lamarre N, Cockrum P. The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021; 11:754687 Epub 2021 Oct 04
    View PubMed
  34. Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. HPB (Oxford). 2020 Dec; 22 (12):1745-1752 Epub 2020 Apr 27
    View PubMed
  35. Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, Chiorean EG, Waterhouse DM, Guiterrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce DW, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res. 2020 Sep 15; 26 (18):4814-4822 Epub 2020 June 18
    View PubMed
  36. Barnes CA, Aldakkak M, Christians KK, Clarke CN, Dua K, George B, Ritch PS, Kamgar M, Hall WA, Kulkarni N, Erickson BA, Evans DB, Tsai S. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery. 2020 Sep; 168 (3):440-447 Epub 2020 July 05
    View PubMed
  37. George B. Safety & Efficacy of Trifluridine/Tipiracil in Metastatic Gastric Cancer Oncology Times. 2020; 42(10):1, 10-11.
  38. Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, Barnes CA, Christians KK, Dua K, Griffin M, Hagen C, Hall WA, Erickson BA, Evans DB. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg. 2020 Apr; 271 (4):740-747
    View PubMed
  39. Krepline AN, Bliss L, Geurts J, Akinola I, Christians KK, George B, Ritch PS, Hall WA, Erickson BA, Evans DB, Tsai S. Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? J Gastrointest Surg. 2020 Feb; 24 (2):235-242 Epub 2019 Nov 19
    View PubMed
  40. Wittmann D, Hall WA, Christians KK, Barnes CA, Jariwalla NR, Aldakkak M, Clarke CN, George B, Ritch PS, Riese M, Khan AH, Kulkarni N, Evans J, Erickson BA, Evans DB, Tsai S. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Front Oncol. 2020; 10:460 Epub 2020 Apr 15
    View PubMed
  41. Barnes CA, Aldakkak M, Clarke CN, Christians KK, Bucklan D, Holt M, Tolat P, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Value of Pretreatment (18)F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Front Oncol. 2020; 10:500 Epub 2020 Apr 17
    View PubMed
  42. Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K. Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial. JAMA Oncol. 2020 Jan 1; 6 (1):e193531 Epub 2020 Jan 09
    View PubMed
  43. Stein A, Strong E, Clark Gamblin T, Clarke C, Tsai S, Thomas J, George B, Mogal H. Molecular and Genetic Markers in Appendiceal Mucinous Tumors: A Systematic Review. Ann Surg Oncol. 2020 Jan; 27 (1):85-97 Epub 2019 Oct 03
    View PubMed
  44. Jariwalla NR, Khan AH, Dua K, Christians KK, Clarke CN, Aldakkak M, George B, Tutton S, Rilling W, Erickson B, Evans DB, Tsai S. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019 Dec; 26 (13):4515-4521 Epub 2019 Oct 22
    View PubMed
  45. Wong M, Kim J, George B, Eriksen C, Pearson T, Robbins J, Zimmerman MA, Hong JC. Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study. J Surg Res. 2019 Oct; 242:23-30 Epub 2019 May 03
    View PubMed
  46. Singavi AK, Ramalingam V, George B. Etanercept for Treatment of Taxane-Induced Pneumonitis. J Oncol Pract. 2019 Oct; 15 (10):556-557 Epub 2019 June 20
    View PubMed
  47. Barnes CA, Chavez MI, Tsai S, Aldakkak M, George B, Ritch PS, Dua K, Clarke CN, Tolat P, Hagen C, Hall WA, Erickson BA, Evans DB, Christians KK. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Surgery. 2019 Sep; 166(3):277-285. Epub 2019 Jul 02.
    View PubMed
  48. Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology. 2019 Jun; 156 (8):2242-2253.e4 Epub 2019 Mar 02
    View PubMed
  49. Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE. Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. J Clin Oncol. 2019 Feb 20; 37 (6):461-470 Epub 2019 Jan 04
    View PubMed
  50. Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019 Feb 1; 7 (1):27 Epub 2019 Feb 01
    View PubMed
  51. Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C. Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. J Immunother Cancer. 2019 Jan 24; 7 (1):18
    View PubMed
  52. Goldman JW, Waterhouse DM, George B, O'Dwyer PJ, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, Kelly K. Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With nab-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer. Front Oncol. 2019; 9:1256 Epub 2019 Nov 26
    View PubMed
  53. Xiong D, Wang Y, Singavi AK, Mackinnon AC, George B, You M. Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer. iScience. 2018 Nov 30; 9:258-277 Epub 2018 Oct 25
    View PubMed
  54. Tsai S, Christians KK, George B, Ritch PS, Dua K, Khan A, Mackinnon AC, Tolat P, Ahmad SA, Hall WA, Erickson BA, Evans DB. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg. 2018 Oct; 268 (4):610-619
    View PubMed
  55. Chatzizacharias NA, Tsai S, Griffin M, Tolat P, Ritch P, George B, Barnes C, Aldakkak M, Khan AH, Hall W, Erickson B, Evans DB, Christians KK. Locally advanced pancreas cancer: Staging and goals of therapy. Surgery. 2018 May; 163 (5):1053-1062 Epub 2018 Jan 10
    View PubMed
  56. Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. Cell. 2017 Nov 16; 171 (5):1042-1056.e10 Epub 2017 Oct 19
    View PubMed
  57. Blitzer GC, Hall WA, Tsai S, Aldakkak M, Hellman RS, Evans DB, Christians KK, George B, Ritch PS, Erickson BA. Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer? Pract Radiat Oncol. 2017 Nov-Dec; 7 (6):e449-e455 Epub 2017 June 29
    View PubMed
  58. Barnes CA, Krepline AN, Aldakkak M, Clarke CN, Christians KK, Khan AH, Hunt BC, Ritch PS, George B, Hall WA, Erickson BA, Evans DB, Tsai S. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? J Gastrointest Surg. 2017 Nov; 21 (11):1793-1803 Epub 2017 Aug 28
    View PubMed
  59. Rajamanickam ES, Christians KK, Aldakkak M, Krepline AN, Ritch PS, George B, Erickson BA, Foley WD, Aburajab M, Evans DB, Tsai S. Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. J Gastrointest Surg. 2017 Mar; 21 (3):496-505 Epub 2016 Nov 28
    View PubMed
  60. Tsai S, Christians KK, Ritch PS, George B, Khan AH, Erickson B, Evans DB. Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. J Oncol Pract. 2016 Oct; 12 (10):915-923
    View PubMed
  61. Krepline AN, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Evans DB, Tsai S. Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated? J Surg Oncol. 2016 Oct; 114 (5):581-586 Epub 2016 Oct 19
    View PubMed
  62. Epperla N, George B. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. J Gastrointest Cancer. 2016 Jun; 47 (2):206-9
    View PubMed
  63. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15 (2):e1-7 Epub 2015 Dec 29
    View PubMed
  64. Christians KK, Heimler JW, George B, Ritch PS, Erickson BA, Johnston F, Tolat PP, Foley WD, Evans DB, Tsai S. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016 Mar; 159 (3):893-900
    View PubMed
  65. Miura JT, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Oshima K, Christians KK, Evans DB, Tsai S. Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. Surgery. 2015 Dec; 158 (6):1545-55 Epub 2015 Aug 01
    View PubMed
  66. Miura JT, Johnston FM, Tsai S, George B, Thomas J, Eastwood D, Banerjee A, Christians KK, Turaga KK, Pawlik TM, Clark Gamblin T. Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2015 Oct; 22 (11):3716-23 Epub 2015 Mar 17
    View PubMed
  67. Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford). 2015 Oct; 17 (10):942-52 Epub 2015 Aug 10
    View PubMed
  68. Fathi A, Christians KK, George B, Ritch PS, Erickson BA, Tolat P, Johnston FM, Evans DB, Tsai S. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest Oncol. 2015 Aug; 6 (4):418-29
    View PubMed
  69. Humphrey SR, Hussain AS, Chandran R, Wilson B, George B. Acute Onset of Acrokeratosis Paraneoplastica (Bazex Syndrome). JAMA Dermatol. 2015 Jun; 151 (6):677-8
    View PubMed
  70. Jayakrishnan TT, Nadeem H, Groeschl RT, George B, Thomas JP, Ritch PS, Christians KK, Tsai S, Evans DB, Pappas SG, Gamblin TC, Turaga KK. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. HPB (Oxford). 2015 Feb; 17 (2):131-9 Epub 2014 Aug 15
    View PubMed
  71. Miura JT, Xiu J, Thomas J, George B, Carron BR, Tsai S, Johnston FM, Turaga KK, Gamblin TC. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biol Ther. 2015; 16 (5):764-9 Epub 2015 Mar 16
    View PubMed
  72. Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS One. 2015; 10 (10):e0139940 Epub 2015 Oct 08
    View PubMed
  73. Krepline AN, Christians KK, Duelge K, Mahmoud A, Ritch P, George B, Erickson BA, Foley WD, Quebbeman EJ, Turaga KK, Johnston FM, Gamblin TC, Evans DB, Tsai S. Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. J Gastrointest Surg. 2014 Nov; 18 (11):2016-25 Epub 2014 Sept 17
    View PubMed
  74. Kharofa J, Tsai S, Kelly T, Wood C, George B, Ritch P, Wiebe L, Christians K, Evans DB, Erickson B. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Radiother Oncol. 2014 Oct; 113 (1):41-6 Epub 2014 Oct 15
    View PubMed
  75. Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC. Molecular profiling in gastric cancer: examining potential targets for chemotherapy. J Surg Oncol. 2014 Sep; 110 (3):302-6 Epub 2014 May 21
    View PubMed
  76. Hwang M, Jayakrishnan TT, Green DE, George B, Thomas JP, Groeschl RT, Erickson B, Pappas SG, Gamblin TC, Turaga KK. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 2014 Jul; 50 (10):1747-1757 Epub 2014 Apr 21
    View PubMed
  77. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Pappas S, Gamblin TC, Turaga KK. Management of acute cholecystitis in cancer patients: a comparative effectiveness approach. Surg Endosc. 2014 May; 28 (5):1505-14 Epub 2014 Apr 01
    View PubMed
  78. Christians KK, Pilgrim CH, Tsai S, Ritch P, George B, Erickson B, Tolat P, Evans DB. Arterial resection at the time of pancreatectomy for cancer. Surgery. 2014 May; 155 (5):919-26 Epub 2014 Jan 22
    View PubMed
  79. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014 Mar; 19 (3):266-74 Epub 2014 Feb 25
    View PubMed
  80. Jayakrishnan TT, Groeschl RT, George B, Thomas JP, Clark Gamblin T, Turaga KK. Review of the impact of antineoplastic therapies on the risk for cholelithiasis and acute cholecystitis. Ann Surg Oncol. 2014 Jan; 21 (1):240-7 Epub 2013 Oct 10
    View PubMed
  81. Wilson JM, Groeschl R, George B, Turaga KK, Patel PJ, Saeian K, Gamblin TC. Ciliated hepatic cyst leading to squamous cell carcinoma of the liver - A case report and review of the literature. Int J Surg Case Rep. 2013; 4 (11):972-5 Epub 2013 Aug 13
    View PubMed
  82. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11 (3):191-4 Epub 2012 Jan 26
    View PubMed
  83. Olteanu H, Harrington AM, George B, Hari PN, Bredeson C, Kroft SH. High prevalence of Dapsone-induced oxidant hemolysis in North American SCT recipients without glucose-6-phosphate-dehydrogenase deficiency. Bone Marrow Transplant. 2012 Mar; 47(3):399-403. Epub 2011 Apr 11.
    View PubMed
  84. George B, Kopetz S. Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep. 2011 Jun; 13 (3):206-15
    View PubMed
  85. George B, Wirostko WJ, Connor TB, Choong NW. Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. J Thorac Oncol. 2009 May; 4 (5):661-2
    View PubMed
  86. George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, Groshen S, Stein J, Skinner D, Jones PA, Cote RJ. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007 Dec 1; 25 (34):5352-8
    View PubMed
  87. Mitra AP, Almal AA, George B, Fry DW, Lenehan PF, Pagliarulo V, Cote RJ, Datar RH, Worzel WP. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer. 2006 Jun 16; 6:159 Epub 2006 June 16
    View PubMed
  88. Chatterjee SJ, George B, Goebell PJ, Alavi-Tafreshi M, Shi SR, Fung YK, Jones PA, Cordon-Cardo C, Datar RH, Cote RJ. Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol. 2004 Jul; 203 (3):762-70
    View PubMed
  89. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004 Mar 15; 22 (6):1007-13 Epub 2004 Feb 23
    View PubMed
  90. Pagliarulo V, George B, Beil SJ, Groshen S, Laird PW, Cai J, Willey J, Cote RJ, Datar RH. Sensitivity and reproducibility of standardized-competitive RT-PCR for transcript quantification and its comparison with real time RT-PCR. Mol Cancer. 2004 Jan 23; 3:5
    View PubMed
  91. George B, Cote RJ, Datar RH. Nucleic acids in disease prognosis. Natl Med J India. 2001 May-Jun; 14 (3):163-7
    View PubMed